摘要
目的 观察吡柔比星辅助化疗方案治疗老年人恶性淋巴瘤的临床效果.方法 将我院2012年8月至2014年8月收治的50例老年恶性淋巴瘤患者作为研究对象,随机将其分为对照组与观察组各25例.对照组给予吡柔比星辅助化疗方案（CTOP）,对照组行CHOP化疗.比较两组患者的治疗情况,记录并发症发生率,观察患者骨髓抑制反应的发生情况.结果 观察组治疗有效率为88.0％,并发症发生率为20.0％,对照组治疗有效率为48.0％,并发症发生率为60.0％,两组治疗有效率及并发症发生率对比差异有统计学意义（P＜0.05）.结论 在老年恶性淋巴瘤患者的临床治疗中,应用吡柔比星辅助化疗方案,临床缓解率高,不良反应发生率低,且可减轻化疗药物对患者的心脏毒性,优化其生存质量,有较高的临床推广价值.
Objective To observe the clinical effect of pirarubicin adjuvant chemotherapy in the treatment of malignant lymphoma in the elderly.Methods 50 elderly patients with malignant lymphoma in our hospital from August 2012 to August 2014 were selected as the research object and randomly divided into control group and observation group with 25 cases in each group.Observation group was treated with pirarubicin adjuvant chemotherapy （CTOP）, while control group was treated with CHOP chemotherapy.Compared treatment condition of two groups, recorded the rate of complications and bone marrow inhibition reaction.Results The therapeutic effective rate of observation group was 88.0%, the rate of complications was 20.0%, those of control group were 48.0% and 60.0%, with statistically significant differences between two groups （P〈0.05）.Conclusions Pirarubicin adjuvant chemotherapy has high clinical remission rate and low incidence of adverse reactions in the treatment of malignant lymphoma in the elderly, which can reduce the chemotherapeutic toxicity to patients＆#39; heart, optimize the survival quality, and is of higher clinical promotional value.
出处
《国际医药卫生导报》
2015年第20期2980-2982,共3页
International Medicine and Health Guidance News
关键词
淋巴瘤
老年
吡柔比星
化疗
并发症
Lymphoma
Elderly
Pirarubicin
Chemotherapy
Complication
